Ankit Kansagra, Associate Vice President Oncology Integration and Community Alliance at Tampa General Hospital, Adjunct Professor at UT Southwestern Medical Center, shared a post on X:
“MajesTEC-4: Trial using Tec vs Tec+Len in maintenance post ASCT !
This is early, but the P3 trial of BCMA bispecifics is going to be a huge change in how we manage NDMM. Globally ~180K NDMM are diagnosed, and about ~30-40% are potentially transplant eligible.
Having a therapy post ASCT to deepen the response and achieve close to 100% CR is significant shift in how MM can be treated in future. ”
Other articles featuring Ankit Kansagra on OncoDaily.
